CeloNova BioSciences Announces Financing Arrangement with Congruent Investment Partners and SWK Holdings Corporation
San Antonio – August 7, 2017
CeloNova BioSciences, Inc. (CeloNova), a medical device company that develops, manufactures and markets a family of innovative cardiovascular products based upon its novel Polyzene™-F nanocoating technology, today announced the completion of a 4-year joint financing arrangement with Congruent Investment Partners and SWK Holdings Corporation. The proceeds of this transaction will provide growth capital for CeloNova to continue its upward trajectory in new product initiatives and focus on enrollment in its ongoing clinical trials.
Data Presented at EuroPCR 2017 Reinforce Positive Clinical Benefits of CeloNova BioSciences’ COBRA PzF™ NanoCoated Coronary Stent
Paris – May 23, 2017
CeloNova BioSciences, Inc. (CeloNova) announced positive clinical results from two multicenter trials reinforcing the safety and effectiveness of its first-in-class COBRA PzF™ NanoCoated Coronary Stent (NCS). Updated results from both the post market e-COBRA study and the pivotal PzF™ SHIELD clinical trial were presented this week at the annual EuroPCR Scientific Program in Paris.
CeloNova BioSciences Receives FDA Approval of COBRA PzF™ Stent System
San Antonio, TX – March 1, 2017
CeloNova BioSciences, Inc. (CeloNova) today announced that it has received U.S. Food and Drug Administration (FDA) approval of its first-in-class COBRA PzF™ NanoCoated Coronary Stent System.
CeloNova BioSciences Announces Clinical Results from Pivotal PzF SHIELD Clinical Trial Published in the Journal of the American College of Cardiology: Cardiovascular Interventions
San Antonio, TX – January 24, 2017
CeloNova BioSciences, Inc. (CeloNova) today announced the publication of primary endpoint results from its global, multicenter PzF SHIELD clinical trial evaluating the first-in-class COBRA PzF™ NanoCoated Coronary Stent. The 9-month findings were published in the January 23rd issue of the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.
CeloNova Executive Chairman and Acting CEO Dennert Ware Inducted into Prestigious Texas Business Hall of Fame
San Antonio, TX – November 2, 2016
CeloNova BioSciences, Inc. announced today that the Company’s Executive Chairman and acting CEO, Dennert Ware, was inducted into the Texas Business Hall of Fame at the 34th Annual Induction Dinner held in San Antonio on Thursday, October 27.
CeloNova BioSciences Announces Key Activities for Transcatheter Cardiovascular Therapeutics (TCT) Meeting 2016
San Antonio, TX, October 25, 2016
CeloNova BioSciences, Inc. announced today its key activities at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) Annual Congress, which will take place October 29 – November 2 in Washington, D.C. Preliminary clinical data, including primary endpoint, from the COBRA PzF NanoCoated Coronary Stent development program will be presented.
CeloNova enrolls first patient in COBRA reduce trial for patients at high risk of bleeding
San Antonio, TX, February 8, 2016
CeloNova BioSciences, Inc. (CeloNova) announced today that the first patient has been enrolled in its highly anticipated COBRA REDUCE trial. The COBRA REDUCE trial recently received conditional FDA approval and will study the COBRA PzF nanocoated coronary stent (NCS) system in patients at high risk of bleeding.
Boston Scientific to acquire interventional radiology business of CeloNova biosciences
Marlborough, MA, November 10, 2015
Boston Scientific (NYSE: BSX) has entered into a definitive agreement to acquire the interventional radiology portfolio of CeloNova Biosciences, a San Antonio-based developer of endovascular and interventional cardiology technologies.
First patient enrolled in CeloNova’s e-COBRA clinical registry
San Antonio, TX, September 22, 2015
CeloNova BioSciences, Inc. (CN) has announced that it enrolled the first patient in its multicenter e-COBRA clinical study in France. This prospective registry will further assess the safety and efficacy of the novel COBRA PzF coronary stent system in real world and complex patients with heart disease.
CeloNova announces accelerated IDE trial enrollment completion for its COBRA PzF coronary stent system
San Antonio, TX, February 19, 2015
CeloNova BioSciences, Inc. (San Antonio, TX) announced completion of patient enrollment in the global, multi-center IDE trial for its COBRA PzF stent. Completed enrollment was ahead of schedule and supports submission for FDA approval of the novel COBRA PzF stent with its advanced, nano-thin coating of Polyzene-F polymer.
First-in-man study of the COBRA PzF coronary stent shows promising results highlighted by short, 30-day dual-antiplatelet therapy and low, 3% TLR rate
San Antonio, TX, September 16, 2014
CeloNova BioSciences, Inc., today announced that positive First-in-Man (FIM) clinical trial results found its COBRA PzF coronary stent system with an advanced nano-thin coating of Polyzene-F polymer to be a safe and effective routine interventional treatment for real-world and complex patients with heart disease.
CeloNova’s coronary stent system could mean faster healing of arteries and greatly reduced use of blood-thinning medication
San Antonio, TX, March 20, 2014
CeloNova BioSciences announced that the U.S. Food and Drug Administration (FDA) has granted approval to start an IDE trial for its novel coronary stent system – the Cobra PzF coronary stent system.
May 10 – May 13, 2017
New Orleans, LA
Join CeloNova BioSciences at SCAI 2017 on May 12th, 2017 from 6:45am-7:45am. CeloNova will be hosting the COBRA PzF NanoCoated Stent Symposium – RETHINK DAPT: Optimizing PCI in high-bleeding risk patients with COBRA PzF NanoCoated Stent (NCS)* in the Fulton Room on the 3rd level.